Nuclear Medicine

Prof. Dr. Savaş Karyağar

Thyroid NeoplasmsUrinary Tract InfectionsProstatic NeoplasmsColorectal NeoplasmsSkin NeoplasmsAdenocarcinomaCarcinoma, Non-Small-Cell Lung

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Thyroid Neoplasms 5 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Urinary Tract Infections 3 publications
  • Prostatic Neoplasms 2 publications
  • Colorectal Neoplasms 2 publications
  • Skin Neoplasms 2 publications
  • Adenocarcinoma 2 publications
  • Carcinoma, Non-Small-Cell Lung 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyNuclear Medicinesaglik.gov.trFrom source
  • Institutionİstanbul Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesisaglik.gov.trFrom source
  • Area of workThyroid NeoplasmsExtracted from 5 publications · Model version —From source
  • Publications55 publicationsOpenAlex, ORCID, Europe PMCFrom source
  • ORCID0000-0002-3259-9666ORCIDFrom source
  • Last synchronised5 November 2026 08:55https://cemiltascioglush.saglik.gov.tr/TR-1563433/doktorlarimiz.html#savas-karyagarsaglik.gov.tr

Scientific work

Publications on Thyroid Neoplasms

55 publications
  1. Prognostic value of PSMA PET–derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Imaging, 2026

    DOI 10.1186/s40644-026-01036-6 PMID 42063136 Open-access full textSource: OpenAlex

  2. A Case of Incidental Adenoid Cystic Carcinoma of the Trachea on Gallium-68 PSMA PET/CT Imaging

    Clinical Nuclear Medicine, 2026

    DOI 10.1097/rlu.0000000000006458 PMID 41954949 Source: OpenAlex

  3. Can Hemogram Parameters Be Used as a Biomarker for Thyroid Carcinomas?

    Annali Italiani di Chirurgia, 2025

    DOI 10.62713/aic.4054 PMID 41243539 Open-access full textSource: ORCID

  4. A comparison of image quality between digital and analog pet for spatial resolution: A phantom study

    International Journal of Radiation Research, 2025

    DOI 10.61186/ijrr.23.2.19 Open-access full textSource: OpenAlex

  5. Graves’ disease: is hyperthyroidism still present 6 months after radioactive iodine treatment really a failure?

    Nuclear Medicine Communications, 2025

    DOI 10.1097/mnm.0000000000002033 PMID 40814180 1 citation (OpenAlex) Source: OpenAlex

  6. Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer

    Molecular imaging and radionuclide therapy, 2023

    DOI 10.4274/mirt.galenos.2022.05826 PMID 37337764 4 citations (Europe PMC) Open-access full textSource: Europe PMC

  7. Unusual spread of the follicular thyroid carcinoma, metastases to liver and pancreas

    Médecine Nucléaire, 2023

    DOI 10.1016/j.mednuc.2023.03.010 Source: ORCID

  8. How reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMA

    Nuclear Medicine Communications, 2023

    DOI 10.1097/mnm.0000000000001722 PMID 37334538 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  9. The Predictive Value of Baseline Volumetric PET/CT Parameters on Treatment Response and Prognosis in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy

    Journal of Gastrointestinal Cancer, 2021

    DOI 10.1007/s12029-021-00608-y PMID 33651265 11 citations (Europe PMC) Open-access full textSource: OpenAlex

  10. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?

    Nuclear Medicine Communications, 2021

    DOI 10.1097/mnm.0000000000001431 PMID 33958536 7 citations (Europe PMC) Source: ORCID

View all 55 publications